Enrolling
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
J2J-MC-JZLH - ClinicalTrials.gov - NCT05514054
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).
Enter your city or zip code to find the nearest site
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Breast CancerWhat the trial is testing?
Anastrozole, Exemestane, Imlunestrant, Letrozole, TamoxifenCould I receive a Placebo?
NoEnrollment Goal
6000Trial Dates
Oct 4, 2022 - Mar 2032How long will I be in the trial?
Study participation could last up to 10 years.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
- Have early-stage ER+ HER2- breast cancer
- Have already had surgery to treat the breast cancer
- Have higher-than-average risk for the breast cancer to come back
- Have been taking a drug that blocks the production/action of estrogen for the last two to five years
- Be able to walk and able to carry out light work
- Have adequate body organ function
Participants Must Not:
- Have breast cancer that is advanced or has spread to another part(s) of the body
- Have a serious medical condition (other than this cancer)
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo